Pharmaron Beijing (HKG:3759, SHE:300759) expects attributable net profit of 729.5 million yuan to 771.5 million yuan for the six months ended June 30, up 4% to 10% from 701.4 million yuan a year earlier, according to a Monday filing with the Hong Kong bourse.
The pharmaceutical company expects first-half revenue of 7.47 billion yuan to 7.66 billion yuan, up 16% to 19% from 6.44 billion yuan in the prior-year period.
Pharmaron attributed the expected growth to stronger strategic customer demand and robust growth in its small-molecule CDMO business, with newly signed orders rising more than 30% in the first half.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments